Finally, we cannot exclude possible effects of concurrent medical treatments that reduce body weight, such as diabetes therapy with glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors. This evidence concerns the gene SLC5A2 and diabetes mellitus.